| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.8 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.8 |